You can read the full publication in The Lancet Diabetes & Endocrinology , titled Tirzepatide and muscle composition changes in people with type 2 diabetes: A post-hoc analysis from a randomised, open-label, parallel-group, phase 3 trial (SURPASS-3 MRI) , here
Yamada T, Wakabayashi M, Bhalla A, Chopra N, Miyashita H, Mikami T, Ueyama H, Fujisaki T, Saigusa Y, Yamaji T, et al
doi: 10.1016/j.neuroscience.2014.02.022 24 CalsolaroV.EdisonP
12 Less than 2 weeks after presentation of STEP-HFpEF, semaglutide was in the headlines again, but this time for a report published in the NEJM detailing its potential benefit among patients with newly diagnosed type 1 diabetes